Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Misoprostol or methylergometrine plus oxytocin versus oxytocin alone for prevention of postpartum hemorrhage after cesarean section
IRCT20230227057554N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in postpartum hemorrhage (PPH) comparing Oxytocin + misoprostol, Oxytocin + methylergometrine and Oxytocin alone (3 arms). Primary endpoints: Incidence of postpartum hemorrhage, Hemoglobin concentration 6 hours after cesarean section and 1 more. Started May 2023; status: completed.
02
Drugs
misoprostolmethylergometrineoxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on IRCT20230227057554N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230227057554N1.